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Activation of IgG+ memory B cells accounts for much of the antibodies in secondary immune responses.
Here, Kometani et al. (2013) demonstrate that reduced amounts of Bach2 in antigen-experienced memory
B cells control the robust production of IgG1+ plasma cells.Memory B cell responses result in rapid
and robust production of circulating
immunoglobulin G (IgG), preferentially, in
response to their stimulation by specific
antigen (Shlomchik and Weisel, 2012).
The predominance of IgG over IgM is of
practical interest because most high-
affinity antibodies are of the IgG subclass.
Initially, investigators focused on the
obvious differences between B cell
receptors (BCRs) of naive IgM+IgD+ B
cells versus IgG+ memory cells. IgM and
IgD each possess short (three residues)
cytoplasmic domains, whereas the highly
conserved cytoplasmic domains of IgG
(cytoplasmic tails) comprise 28 residues.
The longer tails of IgG are crucial for
memory antibody responses (Kaisho
et al., 1997; Martin and Goodnow, 2002).
This suggests that the tails generate
distinct signals in response to antigenic
stimulation. However, BCR-extrinsic
changes including the expression of
transcription factors are implicated as
well (Good and Tangye, 2007). How
does priming of B cells through antigen
experience enhance the responsiveness
of IgG+ memory cells? Furthering our
understanding of memory B cell biology
is crucial for predicting the outcomes
of humoral responses and for rational
design of vaccines.
In the current issue of Immunity, Kome-
tani et al. (2013) demonstrate that both
BCR-intrinsic and -extrinsic mechanisms
collaborate in rapid recall responses
of IgG1+ memory cells. The authors
employed the well-characterized T cell-
dependent response to the hapten nitro-
phenol (4-hydroxyphenylacetyl [NP]).
First, they confirmed that IgG1+ memory
cells are essential components of anti-
NP secondary responses in mice with
conditionally expressed human diphtheria
toxin receptors. Depletion of IgG1+ mem-
ory cells by injection of diphtheria toxineffectively blocked secondary humoral
responses after immunization with NP-
chicken gamma globulin (NP-CGG). In
turn, IgG1+ secondary responses against
NP-CGG were much more effective after
the transfer of IgG1+ memory B cells
with high-affinity NP-specific BCRs (from
B1-8hi gene-targeted mice) rather than
IgM+ B cells with the same antigen
specificity into CGG-primed mice. A key
observation was the increased capacity
of IgG1+ memory B cells to differentiate
into CD138+ plasma cells, instead of
participating in germinal center reactions,
in response to antigenic challenge.
Importantly, expression of high-affinity
IgG1 on B cells was insufficient to estab-
lish an enhanced potential for terminal
differentiation. This point was made
elegantly through the use of naive or
antigen ‘‘inexperienced’’ IgG1+ B cells.
Production of these cells was particularly
difficult because antigen encounter
normally is required for IgG+ B cells. To
overcome this hurdle, the authors derived
naive and memory IgG1+ B cells with
IgG1-ES mice, which were produced by
transfer of nuclei from B1-8hi C57BL/6
Igl+CD38+IgG1+ memory cells (NP-
specific) into enucleated unfertilized
mouse eggs, followed by transfer of
resulting blastocyst-derived ESCs into
normal BALB/c recipient blastocysts.
The resulting chimeric mice generated
NP+IgG1+ B cells with BCRs that repro-
duced the affinity for NP of the original
memory B cells, which was 20-fold
greater than the affinity of Ig on B1-8hi
IgM+IgD+ (referred to hereafter as IgM+)
B cells. Each of these populations was
adoptively transferred into recipients to
test their abilities to mount anti-NP recall
responses. Despite their high-affinity IgG
BCRs, IgG1+ B cells behaved similarly
to IgM+ B cells, with nearly identical
frequencies of proliferation and recruit-Immunment into germinal center reactions and
low rates of differentiation into plasma
cells.
The results suggest that intrinsic
signaling by the IgG1 protein, by itself,
cannot account for the rapid response
of IgG1+ memory cells. Moreover, the
data suggest additional requirements
for in vivo priming by antigen. To test
this hypothesis, the authors evaluated
whether antigen experience increases
the propensity for differentiation of IgG1+
B cells generated by nuclear transfer.
After antigenic stimulation, CD38+IgG1+
memory cells proliferated and differen-
tiated into plasma cells much more effi-
ciently (nearly 6-fold) relative to their naive
counterparts. Thus, antigen experience
establishes a more responsive state
in IgG1+ memory cells, promoting their
expansion and differentiation into plasma
cells.
In search of molecular mechanisms
related to the enhanced responses of
IgG1+ memory B cells, Kometani et al.
(2013) examined key transcriptional
regulators that control differentiation to
plasma cells. Much is known concerning
the transcriptional control of B cell fate
decisions at terminal stages of dif-
ferentiation. In this regard, relative
amounts of the early B cell-specific tran-
scription factor Pax5 and the ‘‘master
regulator’’ of plasma cell differentiation,
Blimp-1 (Prdm1), are centrally important
(Shapiro-Shelef et al., 2005). Pax5 acti-
vates the early program of B cell-specific
genes but is repressed by Blimp-1 during
the transition of B cells to plasma cells. In
turn, Blimp-1 shuts off much of the early
program of expressed genes, including
the Pax5 gene itself.
Pax5 influences the expression of
Blimp-1 via Pax5’s control of BTB and
CNC homolog 2 (Bach2), a BTB-leucine
zipper family transcription factor thatity 39, July 25, 2013 ª2013 Elsevier Inc. 89
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Figure 1. Reduced Levels of Bach2 Promote Robust Differentiation of IgG1+Memory B Cells
to Plasma Cells
Naive (red nuclei) IgM+ and IgG1+ B cells (generated with nuclear transfer-IgG1-ES mice) each respond
weakly to challenge by antigen and produce few plasma cells (green nuclei), resulting in limited amounts
of specific antibodies. In contrast, antigen-experienced IgG1+ memory B cells (CD38+; blue nucleus)
generate plasma cells more efficiently. The authors demonstrate that this is due, in part, to reduced
amounts of the transcription factor Bach2 after priming of naive IgG1+ cells by antigen. Bach2 is not
downregulated similarly in IgM+ memory B cells (not shown). The reduction of Bach2 involves mTOR,
which is activated as part of the PI3K-AKT-mTOR signaling pathway, and Foxo1 (not shown). Bach2
represses expression of Blimp-1 (encoded by Prdm1), the master regulator of plasma cell differentiation.
In the presence of reduced Bach2, Prdm1 promoters are probably poised (hatched arrow) for activation
by signals emanating from antigen engagement of membrane IgG1 and other, yet unidentified cues.
Together, these mechanisms turn on Blimp-1 and the plasma cell program.
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tional repressor (Muto et al., 2010).
Expression of Bach2 is elevated in bone
marrow B cell progenitors and decreases
with developmental progression until it is
absent in terminally differentiated plasma
cells. This pattern parallels the regulation
of Bach2 gene transcription by Pax5
(Schebesta et al., 2007). Notably, Bach2
represses expression of Blimp-1 (Muto
et al., 2010). By repressing Blimp-1, and
thus plasma cell differentiation, Bach2
promotes secondary responses by ‘‘fine
tuning’’ Ig heavy chain class switching
(CSR). Bach2 may prolong expression
of activation-induced cytidine deaminase
(AID), which is essential for germinal
center functions including CSR. Thus,90 Immunity 39, July 25, 2013 ª2013 ElseviePax5, Bach2, and Blimp-1 function
together in a double negative-feedback
loop during B cell terminal differentiation.
Pax5, Bach2, and a third transcription
factor gene, Bcl6 (crucial for germinal
center formation), are each significantly
downregulated in IgG1+ memory B cells
relative to naive IgG1+ B cells. Analysis
of transcription factor expression in naive
IgM+ B cells versus IgG1+ memory cells
from B1-8hi mice showed that both cell
types express low amounts of transcrip-
tion factor transcripts associated with
plasma cells, including Prdm1, Irf4, and
Xbp1. However, IgG1+ memory cells
possessed significantly decreased Pax5,
Bach2, and Bcl6 transcripts relative to
naive IgM+ cells. Reduced Bach2 ex-r Inc.pression in IgG1+ memory B cells relative
to IgM+ naive or memory B cells was
confirmed at the protein level. Although
the reduction in Pax5 may not be func-
tionally significant, the large decrease in
Bach2 in IgG1+ memory cells is likely to
have consequences. This was confirmed
by retroviral transduction of B1-8hi IgM+
cells with shRNAs specific for Bach2 or
Pax5 mRNAs. After transfer into naive
mice and immunization with NP-CGG,
depletion of Bach2 nearly doubled the
frequency of CD138+ plasma cells. Little
or no change was observed with deple-
tion of Pax5. Haploinsufficient expres-
sion of Bach2 in IgG1+ memory cells
also increased plasma cell production.
Together, these results suggest that
reduced Bach2 in IgG1+ memory B cells
predisposes terminal differentiation to
plasma cells in secondary humoral
responses.
Consequences of antigen signaling
through the BCR are understood in
considerable detail, but how does
signaling by IgG1 mediate the reduced
dosage of Bach2? To address this ques-
tion, the authors purified splenic B cells
from wild-type C57BL/6 mice for culture
with inhibitors of signaling pathways.
The cells were activated with anti-CD40,
IL-4, and anti-IgM prior to assessing
amounts of Bach2 transcripts. Bach2
expression was significantly increased
by coincubation with rapamycin, suggest-
ing that the Bach2 gene is repressed
by the mammalian target of rapamycin
(mTOR), a component of the PI3K-AKT-
mTOR pathway. Moreover, rapamycin
reversed the suppression of Bach2 in
response to immunization. A role for
mTOR is a tantalizing link with BCR
signaling, but how does it affect Bach2
transcription directly? In response to this
question, a potential role of the Foxo1
transcription factor was explored
because of its regulation by AKT-medi-
ated phosphorylation. Inhibition of Foxo1
increased silencing of Bach2, whereas
constitutively active Foxo1 increased
Bach2 transcripts in naive IgM+ B cells.
Although somewhat preliminary, the data
suggest that PI3K-AKT-mTOR signaling
may downregulate Bach2 via Foxo1 in
the course of immunization, resulting in
changes in responsiveness and differenti-
ation of IgG1+ memory B cells (Figure 1).
The current study contributes much
new information concerning memory B
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raises additional questions. The new
functions of Bach2 and PI3K-AKT-mTOR
signaling suggest pathways to plasma
cell differentiation, but how are these
mechanisms linked with cytoplasmic
tails of IgG? As the authors point out, the
IgG1 tail may facilitate Bach2 down-
regulation. PI3K-AKT-mTOR signaling
could be qualitatively and/or quantita-
tively enhanced by the IgG tail. In addition,
are other genes involved? Horikawa
et al. (2007) have demonstrated extensive
changes in gene expression resulting
from BCR signaling by the IgG tail. These
data suggest that additional differences in
signaling remain to be elucidated.
Bach2 is also important for differen-
tiation in T cells (Roychoudhuri et al.,
2013). Targeted deletion of Bach2 dem-onstrates its immunoregulatory role in
T cell development. Bach2 represses
effector programs in multiple CD4+ T cell
subsets, including regulatory T cells.
Clearly, further investigation is needed to
understand the scope of Bach2’s func-
tions in B cells as well as T cells. In the
meantime the present study reveals that
as in the labor market, so follows plasma
cell differentiation: experience matters!REFERENCES
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The tyrosine phosphatase PTPN22 regulates T cell receptor signaling. In this issue of Immunity, Wang et al.
(2013) show that inmyeloid cells PTPN22 potentiates TLR-induced type I interferon production and that auto-
immunity-associated allele PTPN22W encodes a reduced-function variant.Protein tyrosine phosphatase nonrecep-
tor type 22 (PTPN22, also termed Lyp
and encoded by PTPN22) is preferentially
expressed in hematopoietic and immune
cells. The role of PTPN22 and its murine
ortholog Ptpn22 (also termed PEP and
encoded by Ptpn22) has attracted intense
investigation because allelic variants of
PTPN22 have been identified as one of
the strongest genetic risk factors for a
variety of autoimmune diseases, including
type I diabetes, rheumatoid arthritis (RA),
systemic lupus erythematosus (SLE), Ha-
shimoto’s thyroiditis, and Graves disease
(Burn et al., 2011; Zheng et al., 2012). The
autoimmune disease-associated risk
allele of PTPN22 encodes a substitutionof tryptophan (W) for arginine (R) at
position 620 (R620W) and is termed
PTPN22W, whereas the nonrisk allele is
PTPN22R. Many PTPN22W-associated
diseases are characterized by dysregu-
lated adaptive immunity and autoanti-
body production.
PTPN22 is expressed in many immune
cell types, including T cells, B cells, natu-
ral killer cells, dendritic cells (DCs), and
monocytes and macrophages (reviewed
in Burn et al., 2011). Full-length PTPN22
contains 807 amino acid residues and
several functional domains, including an
amino-terminal catalytic domain and
carboxy-terminal proline-rich motifs,
including a PLPXR motif termed P1 thatharbors the R620W substitution and can
mediate interactions with SH3-containing
proteins. Identified substrates for PTPN22
include multiple activating signaling
molecules such as Src family kinases,
Syk and ZAP70, T cell receptor com-
ponents CD3ε and TCRz, and the E3 ubiq-
uitin ligase Cbl. Although experimental
differences have not been fully recon-
ciled, the preponderance of evidence
indicates that PTPN22 and its murine
ortholog Ptpn22 function as negative reg-
ulators of TCR signaling (Figure 1) and
suggests that PTPN22W represents a
gain-of-function allele with increased
phosphatase activity that attenuates
TCR signaling. Thus, PTPN22W mayity 39, July 25, 2013 ª2013 Elsevier Inc. 91
